Faes Farma SA (0K9H)
London Exchange · UK · prices in EUR · close of 20 Oct 2026
Key indicators
| Last close | EUR 4.830 |
|---|---|
| 52-week range | 4.251 – 5.361 |
| Return, 1 month / 3 months | +3.3% / +6.1% |
| Return, 1 year / 3 years | +10.5% / +73.1% |
| Trend | Uptrend |
| RSI (14) | 56 |
| Volatility (1 year) | 19.2% |
| Worst drawdown (1 year) | -17.7% |
| Average daily value traded | 0.06M EUR |
| Dividend yield | 2.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Faes Farma is a Spanish pharmaceutical company based in the Basque Country. It researches, develops, manufactures and markets prescription medicines, over-the-counter remedies and active pharmaceutical ingredients. Its product range covers allergies, bone health, dermatology and digestive care, and its consumer brands are sold through pharmacies in Spain and in many other countries. The company also supplies pharmaceutical ingredients to other manufacturers and runs its own production facilities, serving patients, pharmacists and healthcare professionals across Europe and beyond.
On this site Faes Farma SA appears as a stock on the London Exchange (UK), code 0K9H, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Faes Farma SA (0K9H) trades on the London Exchange in UK. It last closed at EUR 4.830 on 20 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 1,312 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 10.5% and over the last three months it rose 6.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 56 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.0% | ||
| From 52-week high | -8.5% | ||
| Momentum | 57 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 6.1% | ||
| 6-month return | -0.7% | ||
| 12-month return, skipping the last month | 7.0% | ||
| Stability (higher is calmer) | 83 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 19.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.7% | ||
| Liquidity | 26 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.06M EUR | ||
| Zero-volume days | 3.3% | ||
| Income | 73 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 2.1% | ||
| Years with dividends | 6 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.2% |
|---|---|
| 1 month | +3.3% |
| 3 months | +6.1% |
| 6 months | −0.7% |
| 1 year | +10.5% |
| 3 years | +73.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 4.617 / 4.691 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.126 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jul 2026 | EUR 0.0705 |
| 8 Jan 2026 | EUR 0.0332 |
| 3 Jul 2025 | EUR 0.1118 |
| 9 Jan 2025 | EUR 0.0332 |
| 4 Jul 2024 | EUR 0.0940 |
| 11 Jan 2024 | EUR 0.0316 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.